Search hospitals > New Jersey > Hackensack
John Theurer Cancer Center at Hackensack University Medical Center
Claim this profileHackensack, New Jersey 07601
Global Leader in Leukemia
Global Leader in Lymphoma
Conducts research for Tumors
Conducts research for Cancer
Conducts research for Solid Tumors
346 reported clinical trials
17 medical researchers
Summary
John Theurer Cancer Center at Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Leukemia, Lymphoma, Tumors, Cancer, Solid Tumors and other specialties. John Theurer Cancer Center at Hackensack University Medical Center is involved with conducting 346 clinical trials across 192 conditions. There are 17 research doctors associated with this hospital, such as Martin E Gutierrez, Robert Alter, MD, Tatyana Feldman, MD, and Donna McNamara, MD.Area of expertise
1Leukemia
Global LeaderCD33 positive
FLT3 positive
NPM1-m positive
2Lymphoma
Global LeaderStage IV
Stage III
HBsAg positive
Top PIs
Martin E GutierrezJohn Theurer Cancer Center at Hackensack University Medical Center2 years of reported clinical research
Expert in Solid Tumors
Expert in Tumors
40 reported clinical trials
77 drugs studied
Robert Alter, MDHackensack University Medical Center5 years of reported clinical research
Studies Cancer
Studies Bladder Cancer
15 reported clinical trials
45 drugs studied
Tatyana Feldman, MDHackensack University Medical Center1 year of reported clinical research
Expert in Lymphoma
Studies Hodgkin's Lymphoma
13 reported clinical trials
25 drugs studied
Donna McNamara, MDHackensack University Medical Center2 years of reported clinical research
Studies Ovarian Cancer
Studies Cancer
14 reported clinical trials
44 drugs studied
Clinical Trials running at John Theurer Cancer Center at Hackensack University Medical Center
Solid Tumors
Tumors
Lymphoma
Non-Small Cell Lung Cancer
Breast Cancer
Acute Myeloid Leukemia
Ovarian Cancer
Leukemia
Multiple Myeloma
Plasma Cell Neoplasms
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting2 awards Phase 34 criteria
I-DXd
for Advanced Cancer
This study is in one single group of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of ifinatamab deruxtecan (I-DXd). * Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of I-DXd when administered as a single agent. This study is expected to last approximately 5 years from the time the first participant is enrolled to the time the last participant is off the study. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: * they withdraw * their disease gets worse * they experience unacceptable side effects.
Recruiting1 award Phase 1 & 2
MK-0472 + Pembrolizumab
for Advanced Cancer
This trial is testing a new drug called MK-0472, alone and with other drugs, in patients with advanced or spreading solid tumors. The goal is to see if it is safe and effective in treating these cancers.
Recruiting1 award Phase 1
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at John Theurer Cancer Center at Hackensack University Medical Center?
John Theurer Cancer Center at Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Leukemia, Lymphoma, Tumors, Cancer, Solid Tumors and other specialties. John Theurer Cancer Center at Hackensack University Medical Center is involved with conducting 346 clinical trials across 192 conditions. There are 17 research doctors associated with this hospital, such as Martin E Gutierrez, Robert Alter, MD, Tatyana Feldman, MD, and Donna McNamara, MD.
Where is John Theurer Cancer Center at Hackensack University Medical Center located?
The John Theurer Cancer Center at Hackensack University Medical Center is located at 92 2nd St, Hackensack, NJ 07601. For directions, take the I-80 West to Exit 66 toward Hackensack Avenue South, continue onto Hackensack Avenue, then turn left onto Second Street. The hospital will be on your right.
Who should I call to ask about financial aid or insurance network?
**John Theurer Cancer Center at Hackensack University Medical Center Contact Information:**
- **Financial Assistance Department:** Call 551-996-4343
- **Insurance Department:** Call 855-513-5897
What insurance does John Theurer Cancer Center at Hackensack University Medical Center accept?
The John Theurer Cancer Center at Hackensack University Medical Center accepts a wide range of insurance plans, including Medicare. For information on specific insurance plans and coverage, please contact the hospital directly at 201.666.3900.
What awards or recognition has John Theurer Cancer Center at Hackensack University Medical Center received?
John Theurer Cancer Center at Hackensack University Medical Center is recognized as the best cancer center in New Jersey by U.S. News & World Report and Newsweek. It is part of the National Cancer Institute-approved Georgetown Lombardi Comprehensive Cancer Center Consortium, focusing on improving cancer outcomes and reducing disparities. The center's investigators are pivotal in introducing significant anticancer drugs to the market through unique collaborations.